56 / 62
Trilaciclib preserve HSPCs (myelopreservation), including reduced multi-lineage myelosuppression and reduced supportive care requirements and dose reductions
• Peripheral blood immunophenotyping from this Phase 2 trial) demonstrated that trilaciclib enhances lymphocyte function as measured by:
•
Preservation of circulating B cells and increased number of circulating T cells
•
Preservation of circulating activated CD8+ T and Th1 cells
•
Increased circulating CD8+ T/regulatory T cell ratio
•
The myelopreservation benefits of trilaciclib demonstrated here, in addition to the preclinical murine data, suggest there is potential to enhance the anti-tumor response of a
checkpoint inhibitor + chemotherapy regimen with trilaciclib